This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $700,690 in funding to Health Research, Inc. at Roswell Park to decipher the molecular mechanisms underlying breast cancer bone metastasis. The project aims to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases, and to determine the role of YAP/TAZ-mediated metabolic reprogramming in the early stages of bone metastasis. The research seeks to uncover new therapeutic targets to treat both microscopic and fully developed bone metastases in breast cancer patients. The five-year project period runs from April 1, 2025 to March 31, 2030.
Generated 3/25/25, 2:49 AM